SynthesisInternational urogynecology journal2019
Updating the evidence on drugs to treat overactive bladder: a systematic review.
Synthesis in International urogynecology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2023Pooled it
- Outcome reporting in randomized controlled trials (RCTs) on the pharmacological management of idiopathic overactive bladder (OAB) in women; a systematic review for the development of core outcome sets (COS).International urogynecology journal · 2022Pooled it
- Drug-related Halitosis: A Systematic Review.Oral health & preventive dentistry · 2020Pooled it
- A randomized, unblinded, controlled clinical study to assess the mobile digital health application INKA in the management of therapy refractory overactive bladder and mixed incontinence.Frontiers in digital health · 2026Trial
- Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA-8010 in healthy subjects: First-in-human phase I study.Pharmacology research & perspectives · 2023Trial
- The role of pharmacological interventions in managing urological complications during pregnancy and childbirth: A review.Medicine · 2025Review
- Integrated management strategies for benign prostatic hyperplasia.Frontiers in urology · 2025Review
- An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.CNS drugs · 2024Review
- Drug-Drug Interactions between Tamsulosin and Mirabegron in Healthy Individuals Do Not Affect Pharmacokinetics and Hemodynamic Parameters Significantly.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Evaluation and management of enuresis in the general paediatric setting.Paediatrics & child health · 2023Review
- L'évaluation et la prise en charge de l'énurésie en pédiatrie générale.Paediatrics & child health · 2023Review
- Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives.International journal of women's health · 2023Review
- Combination and Novel Pharmacologic Agents for OAB.Current urology reports · 2022Review
- Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review.Current urology · 2021Review
- Anticholinergic drugs and risk of dementia: Time for action?Pharmacology research & perspectives · 2021Article
- Vaginal laser for overactive bladder syndrome.International urogynecology journal · 2020Article
- Combination pharmacotherapy for the treatment of the overactive bladder syndrome: a new solution for an old problem?International urogynecology journal · 2020Article
- Prevalence and associated risk factors among patients with overactive bladder syndrome in Pakistan.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
introductionOveractive bladder (OAB) is a common condition, increasing with age and affecting quality of life. While numerous OAB drugs are available, persistence is low. We evaluated evidence published since 2012 to determine if newer drugs provided better efficacy and harm profiles.
methodsWe searched MEDLINE and the Cochrane Library from 2012 to September 2018 using terms for included drugs and requested information from manufacturers of included drugs. We performed dual review of all systematic review processes, evaluated study quality, and conducted meta-analyses using random effects models.
resultsIn addition to 31 older studies, we included 20 trials published since 2012 (N = 16,478; 4 good, 11 fair, and 5 poor quality). Where statistical differences were found, they were clinically small (reductions of < 0.5 episodes/day). Solifenacin plus mirabegron improved efficacy outcomes over monotherapy with either drug, but significantly increased constipation compared with solifenacin and dry mouth compared with mirabegron. Solifenacin reduced incontinence over mirabegron and tolterodine and urgency episodes over tolterodine. Mirabegron did not differ from tolterodine in efficacy but had significantly lower incidence of dry mouth than solifenacin or tolterodine. Fesoterodine showed significant improvements but also anticholinergic effects vs. tolterodine. Oxybutynin, solifenacin, and tolterodine had similar efficacy, but dry mouth led to greater discontinuation with oxybutynin. Blurred vision, cardiac arrhythmia, and dizziness were uncommon.
conclusionNew evidence confirms small, but clinically uncertain, differences among monotherapies and also between combination and monotherapy, regardless of statistical significance. While drugs mainly differed in incidence of dry mouth or constipation, none provided improved efficacy without increased harms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.